Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Overall survival in malignant glioma is significantly prolonged by neurosurgical delivery of etoposide and temozolomide from a thermo-responsive biodegradable paste.

Smith SJ, Tyler B, Gould TWA, Veal GJ, Gorelick NL, Rowlinson J, Serra R, Ritchie AA, Berry P, Otto A, Choi J, Skuli N, Estevez-Cebrero MA, Shakesheff KM, Brem H, Grundy RG, Rahman R.

Clin Cancer Res. 2019 May 21. pii: clincanres.3850.2018. doi: 10.1158/1078-0432.CCR-18-3850. [Epub ahead of print]

PMID:
31113843
2.

Solitary sclerosis presenting as isolated spontaneous paroxysmal dysarthria.

Xia Y, Shoemaker T, Gorelick N, McArthur JC.

eNeurologicalSci. 2019 Jan 11;14:98-100. doi: 10.1016/j.ensci.2019.01.001. eCollection 2019 Mar.

3.

Inland surface waters in protected areas globally: Current coverage and 30-year trends.

Bastin L, Gorelick N, Saura S, Bertzky B, Dubois G, Fortin MJ, Pekel JF.

PLoS One. 2019 Jan 17;14(1):e0210496. doi: 10.1371/journal.pone.0210496. eCollection 2019.

4.

Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.

Shapira-Furman T, Serra R, Gorelick N, Doglioli M, Tagliaferri V, Cecia A, Peters M, Kumar A, Rottenberg Y, Langer R, Brem H, Tyler B, Domb AJ.

J Control Release. 2019 Feb 10;295:93-101. doi: 10.1016/j.jconrel.2018.12.048. Epub 2018 Dec 31.

PMID:
30605703
5.

Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system.

Maxwell R, Luksik AS, Garzon-Muvdi T, Hung AL, Kim ES, Wu A, Xia Y, Belcaid Z, Gorelick N, Choi J, Theodros D, Jackson CM, Mathios D, Ye X, Tran PT, Redmond KJ, Brem H, Pardoll DM, Kleinberg LR, Lim M.

Oncoimmunology. 2018 Sep 6;7(12):e1500108. doi: 10.1080/2162402X.2018.1500108. eCollection 2018.

6.

Evaluation of an in vivo model for ventricular shunt infection: a pilot study using a novel antimicrobial-loaded polymer.

Iyer RR, Gorelick N, Carroll K, Blitz AM, Beck S, Garrett CM, Monroe A, Tyler B, Zuckerman ST, Capadona JR, von Recum HA, Luciano MG.

J Neurosurg. 2018 Jul 1:1-9. doi: 10.3171/2018.1.JNS172523. [Epub ahead of print]

PMID:
30074457
7.

Ribavirin as a potential therapeutic for atypical teratoid/rhabdoid tumors.

Casaos J, Huq S, Lott T, Felder R, Choi J, Gorelick N, Peters M, Xia Y, Maxwell R, Zhao T, Ji C, Simon T, Sesen J, Scotland SJ, Kast RE, Rubens J, Raabe E, Eberhart CG, Jackson EM, Brem H, Tyler B, Skuli N.

Oncotarget. 2018 Jan 3;9(8):8054-8067. doi: 10.18632/oncotarget.23883. eCollection 2018 Jan 30.

8.

HIF-1α- Targeting Acriflavine Provides Long Term Survival and Radiological Tumor Response in Brain Cancer Therapy.

Mangraviti A, Raghavan T, Volpin F, Skuli N, Gullotti D, Zhou J, Asnaghi L, Sankey E, Liu A, Wang Y, Lee DH, Gorelick N, Serra R, Peters M, Schriefer D, Delaspre F, Rodriguez FJ, Eberhart CG, Brem H, Olivi A, Tyler B.

Sci Rep. 2017 Nov 2;7(1):14978. doi: 10.1038/s41598-017-14990-w.

9.

Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.

Volpin F, Casaos J, Sesen J, Mangraviti A, Choi J, Gorelick N, Frikeche J, Lott T, Felder R, Scotland SJ, Eisinger-Mathason TSK, Brem H, Tyler B, Skuli N.

Oncogene. 2017 May 25;36(21):3037-3047. doi: 10.1038/onc.2016.457. Epub 2016 Dec 12.

PMID:
27941882
10.

High-resolution mapping of global surface water and its long-term changes.

Pekel JF, Cottam A, Gorelick N, Belward AS.

Nature. 2016 Dec 15;540(7633):418-422. doi: 10.1038/nature20584. Epub 2016 Dec 7.

PMID:
27926733
11.

Evidence for magmatic evolution and diversity on Mars from infrared observations.

Christensen PR, McSween HY, Bandfield JL, Ruff SW, Rogers AD, Hamilton VE, Gorelick N, Wyatt MB, Jakosky BM, Kieffer HH, Malin MC, Moersch JE.

Nature. 2005 Jul 28;436(7050):504-9.

PMID:
16007077
12.

Mineralogy at Meridiani Planum from the Mini-TES Experiment on the Opportunity Rover.

Christensen PR, Wyatt MB, Glotch TD, Rogers AD, Anwar S, Arvidson RE, Bandfield JL, Blaney DL, Budney C, Calvin WM, Fallacaro A, Fergason RL, Gorelick N, Graff TG, Hamilton VE, Hayes AG, Johnson JR, Knudson AT, McSween HY Jr, Mehall GL, Mehall LK, Moersch JE, Morris RV, Smith MD, Squyres SW, Ruff SW, Wolff MJ.

Science. 2004 Dec 3;306(5702):1733-9.

13.

Initial results from the Mini-TES experiment in Gusev Crater from the Spirit Rover.

Christensen PR, Ruff SW, Fergason RL, Knudson AT, Anwar S, Arvidson RE, Bandfield JL, Blaney DL, Budney C, Calvin WM, Glotch TD, Golombek MP, Gorelick N, Graff TG, Hamilton VE, Hayes A, Johnson JR, McSween HY Jr, Mehall GL, Mehall LK, Moersch JE, Morris RV, Rogers AD, Smith MD, Squyres SW, Wolff MJ, Wyatt MB.

Science. 2004 Aug 6;305(5685):837-42.

14.

In vivo transgenic mutation assays.

Thybaud V, Dean S, Nohmi T, de Boer J, Douglas GR, Glickman BW, Gorelick NJ, Heddle JA, Heflich RH, Lambert I, Martus HJ, Mirsalis JC, Suzuki T, Yajima N.

Mutat Res. 2003 Oct 7;540(2):141-51.

PMID:
14550498
15.

Morphology and composition of the surface of Mars: Mars Odyssey THEMIS results.

Christensen PR, Bandfield JL, Bell JF 3rd, Gorelick N, Hamilton VE, Ivanov A, Jakosky BM, Kieffer HH, Lane MD, Malin MC, McConnochie T, McEwen AS, McSween HY Jr, Mehall GL, Moersch JE, Nealson KH, Rice JW Jr, Richardson MI, Ruff SW, Smith MD, Titus TN, Wyatt MB.

Science. 2003 Jun 27;300(5628):2056-61. Epub 2003 Jun 5.

16.

In vivo transgenic mutation assays.

Heddle JA, Dean S, Nohmi T, Boerrigter M, Casciano D, Douglas GR, Glickman BW, Gorelick NJ, Mirsalis JC, Martus HJ, Skopek TR, Thybaud V, Tindall KR, Yajima N.

Environ Mol Mutagen. 2000;35(3):253-9.

PMID:
10737959
17.

Detection of cyclophosphamide-induced mutations at the Hprt but not the lacI locus in splenic lymphocytes of exposed mice.

Walker VE, Andrews JL, Upton PB, Skopek TR, deBoer JG, Walker DM, Shi X, Sussman HE, Gorelick NJ.

Environ Mol Mutagen. 1999;34(2-3):167-81.

PMID:
10529741
18.

Tissue-specific mutant frequencies and mutational spectra in cyclophosphamide-treated lacI transgenic mice.

Gorelick NJ, Andrews JL, deBoer JG, Young R, Gibson DP, Walker VE.

Environ Mol Mutagen. 1999;34(2-3):154-66.

PMID:
10529740
19.

Spontaneous mutation in lacI transgenic mice: a comparison of tissues.

de Boer JG, Provost S, Gorelick N, Tindall K, Glickman BW.

Mutagenesis. 1998 Mar;13(2):109-14.

PMID:
9568581
20.

Databases and software for the analysis of mutations in the human p53 gene, human hprt gene and both the lacI and lacZ gene in transgenic rodents.

Cariello NF, Douglas GR, Gorelick NJ, Hart DW, Wilson JD, Soussi T.

Nucleic Acids Res. 1998 Jan 1;26(1):198-9.

21.

Sources of variability in data from a positive selection lacZ transgenic mouse mutation assay: an interlaboratory study.

Piegorsch WW, Lockhart AC, Carr GJ, Margolin BH, Brooks T, Douglas GR, Liegibel UM, Suzuki T, Thybaud V, van Delft JH, Gorelick NJ.

Mutat Res. 1997 Feb 14;388(2-3):249-89.

PMID:
9057887
23.

Mutation assays in male germ cells from transgenic mice: overview of study and conclusions.

Ashby J, Gorelick NJ, Shelby MD.

Mutat Res. 1997 Feb 14;388(2-3):111-22. Review.

PMID:
9057871
24.

Databases and software for the analysis of mutations in the human p53 gene, the human hprt gene and both the lacI and lacZ gene in transgenic rodents.

Cariello NF, Douglas GR, Dycaico MJ, Gorelick NJ, Provost GS, Soussi T.

Nucleic Acids Res. 1997 Jan 1;25(1):136-7.

25.
26.

Frequency and spectrum of ethylnitrosourea-induced mutation at the hprt and lacI loci in splenic lymphocytes of exposed lacI transgenic mice.

Walker VE, Gorelick NJ, Andrews JL, Craft TR, deBoer JG, Glickman BW, Skopek TR.

Cancer Res. 1996 Oct 15;56(20):4654-61.

27.

A strategy for the application of transgenic rodent mutagenesis assays.

Gorelick NJ, Mirsalis JC.

Environ Mol Mutagen. 1996;28(4):434-42. Review.

PMID:
8991075
28.
29.
30.

The genetic analysis of lacI mutations in sectored plaques from Big Blue transgenic mice.

Stuart GR, Gorelick NJ, Andrews JL, de Boer JG, Glickman BW.

Environ Mol Mutagen. 1996;28(4):385-92.

PMID:
8991067
31.

State of the art in transgenic animals in mutation research.

Gorelick NJ, Tindall KR, Glickman BW.

Environ Mol Mutagen. 1996;28(4):295-8. No abstract available.

PMID:
8991056
32.

Validation issues for the use of transgenic mouse mutation assays in risk assessment.

Gorelick NJ.

Prog Clin Biol Res. 1996;395:81-108. Review. No abstract available.

PMID:
8895985
33.

Genotoxicity in the rodent urinary bladder.

King C, Wang C, Gorelick N, Frederick C.

Food Chem Toxicol. 1995 Sep;33(9):757-69. Review.

PMID:
7557749
34.

Mutational spectra in the lacl gene in skin from 7,12-dimethylbenz[a]anthracene-treated and untreated transgenic mice.

Gorelick NJ, Andrews JL, Gu M, Glickman BW.

Mol Carcinog. 1995 Sep;14(1):53-62.

PMID:
7546225
35.

Genotoxicity of trans-anethole in vitro.

Gorelick NJ.

Mutat Res. 1995 Feb;326(2):199-209.

PMID:
7529885
36.

Statistical design and analysis of mutation studies in transgenic mice.

Carr GJ, Gorelick NJ.

Environ Mol Mutagen. 1995;25(3):246-55. Review.

PMID:
7737142
37.

Overview of mutation assays in transgenic mice for routine testing.

Gorelick NJ.

Environ Mol Mutagen. 1995;25(3):218-30. Review.

PMID:
7737140
39.

Sources of variability in data from a lacI transgenic mouse mutation assay.

Piegorsch WW, Lockhart AM, Margolin BH, Tindall KR, Gorelick NJ, Short JM, Carr GJ, Thompson ED, Shelby MD.

Environ Mol Mutagen. 1994;23(1):17-31.

PMID:
8125080
40.

Overview of the workshops on statistical analysis of mutation data from transgenic mice.

Gorelick NJ, Thompson ED.

Environ Mol Mutagen. 1994;23(1):12-6.

PMID:
7907290
41.

Statistical tests of significance in transgenic mutation assays: considerations on the experimental unit.

Carr GJ, Gorelick NJ.

Environ Mol Mutagen. 1994;24(4):276-82. Review.

PMID:
7851339
42.

Application of HPLC in the 32P-postlabeling assay.

Gorelick NJ.

Mutat Res. 1993 Jul;288(1):5-18. Review.

PMID:
7686266
44.

Risk assessment for aflatoxin: I. Metabolism of aflatoxin B1 by different species.

Gorelick NJ.

Risk Anal. 1990 Dec;10(4):539-59. Review.

PMID:
2287782
45.

Formation of DNA and hemoglobin adducts of fluoranthene after single and multiple exposures.

Gorelick NJ, Hutchins DA, Tannenbaum SR, Wogan GN.

Carcinogenesis. 1989 Sep;10(9):1579-87.

PMID:
2670302
46.

Fluoranthene-DNA adducts: identification and quantification by an HPLC-32P-postlabeling method.

Gorelick NJ, Wogan GN.

Carcinogenesis. 1989 Sep;10(9):1567-77.

PMID:
2670301
47.

EPR and Mössbauer studies of nucleotide-bound nitrogenase iron protein from Azotobacter vinelandii.

Lindahl PA, Gorelick NJ, Münck E, Orme-Johnson WH.

J Biol Chem. 1987 Nov 5;262(31):14945-53.

48.

Chemical and biochemical dosimetry of exposure to genotoxic chemicals.

Wogan GN, Gorelick NJ.

Environ Health Perspect. 1985 Oct;62:5-18.

Supplemental Content

Loading ...
Support Center